BioNTech Investor Day Presentation Deck
2 Variant-adapted vaccines
A science-driven preparedness strategy
ā
ā
Extensive clinical experience with multiple other variant-adapted vaccines
Consistent safety and immunogenicity profiles
Robust manufacturing process
Requires minimal changes to introduce updated antigen sequence for new variant/sublineage
As of today, safety profile of COMIRNATY is well characterized
Extensive post-marketing exposure and close monitoring
No identification of new important safety issues in pediatric populations as well as with booster
schemes
Discussions with regulators are ongoing to define most appropriate pathways to
leverage current experience and ensure that variant-adapted vaccines can be made
available in the future to timely address newly emerging variants / sublineages
[DAN
CAR
Pandemic prep.
Pfizer
Pfizer BIONTECH
80View entire presentation